Showing results (81-90 of 548) with videos related to
Sort By:
Pageof 55
Cardiology Clinics|July 13, 2010
The contribution of early nephropathy to cardiovascular riskTamar S Polonsky, Francesco LocatelliKidney International|May 20, 2023
Quality of life: a crucial aspect for the patients, a neglected goal in the treatment of anemia in patients with CKDFrancesco Locatelli, Lucia Del VecchioContributions to Nephrology|August 9, 2007
Clinical aspects of haemodiafiltrationFrancesco Locatelli, Salvatore Di FilippoExpert Opinion on Investigational Drugs|July 6, 2018
Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney diseaseLucia Del Vecchio, Francesco LocatelliNephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 11, 2003
Dialysis adequacy and response to erythropoietic agents: what is the evidence base?Francesco Locatelli, Lucia Del VecchioJournal of Nephrology|December 31, 2003
Pure red cell aplasia secondary to treatment with erythropoietinFrancesco Locatelli, Lucia Del VecchioThe Oncologist|September 21, 2011
Erythropoiesis-stimulating agents in renal medicineFrancesco Locatelli, Lucia Del VecchioExpert Opinion on Pharmacotherapy|November 29, 2013
Optimal phosphate control: still an unmet need in chronic kidney disease patientsFrancesco Locatelli, Lucia Del VecchioClinical Kidney Journal|September 9, 2020
Hypoxia response and acute lung and kidney injury: possible implications for therapy of COVID-19Lucia Del Vecchio, Francesco LocatelliCurrent Opinion in Nephrology and Hypertension|May 31, 2018
Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?Francesco Locatelli, Lucia Del VecchioPageof 55